

Closed Topic Search

Enter terms
Search

[Reset](#) Sort By: Close Date (descending)

- [Relevancy \(descending\)](#)
- [Title \(ascending\)](#)
- [Open Date \(descending\)](#)
- [Close Date \(ascending\)](#)
- [Release Date \(descending\)](#)

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.

Displaying 11 - 20 of 1052 results



[1. NIH/NCI 345: Predictive Biomarkers of Adverse Reactions to Radiation Treatment](#)

Release Date: 07-24-2015 Open Date: 07-24-2015 Due Date: 10-16-2015 Close Date: 10-16-2015

Radiotherapy is an important definitive and palliative treatment modality for millions of patients with cancer and is used alone or in combination with drug therapy. However, a variety of patient, tumor, and treatment-related factors will influence its outcome

SBIR Department of Health and Human Services

[2. NIH/NCI 346: Molecularly Targeted Radiation Therapy for Cancer Treatment](#)

Release Date: 07-24-2015 Open Date: 07-24-2015 Due Date: 10-16-2015 Close Date: 10-16-2015

Targeted radionuclide therapy (TRT) enables personalized cancer treatment by combining the therapeutic effect of radiation therapy with the targeting capability of molecular therapies.

SBIR Department of Health and Human Services

[3. NIH/NCI 347: Signal Amplification to Enable Attomolar Quantitation in Slide-Based or ELISA Biomarker Immunoassays](#)

Release Date: 07-24-2015 Open Date: 07-24-2015 Due Date: 10-16-2015 Close Date:

10-16-2015

Accurate detection of specific markers is crucial for the diagnosis of malignant disease, monitoring drug therapy and patient screening.

SBIR Department of Health and Human Services

4. [NIH/NCI 348: Identification and Capture of Enriched Tumor Zones with Preservation of Labile Biomarkers from Ultra-Cold Biopses](#)

Release Date: 07-24-2015 Open Date: 07-24-2015 Due Date: 10-16-2015 Close Date: 10-16-2015

Personalized medicine approaches allow the treatment of patient tumors with drugs tailored to their tumors, which increase the probability of a beneficial response.

SBIR Department of Health and Human Services

5. [NIH/NCI 349: Proximity Slide-Based Sandwich Immunoassay to Visualize Intramolecular Epitopes of Analytes in Tissue Sections](#)

Release Date: 07-24-2015 Open Date: 07-24-2015 Due Date: 10-16-2015 Close Date: 10-16-2015

The cancer community has developed a series of single-plex and multiplex immunofluorescent assays (IFA) to evaluate oncology biomarkers in tumor sections on slides.

SBIR Department of Health and Human Services

6. [NIH/NCI 350: Highly Innovative Tools for Quantifying Redox Effector Dynamics in Cancer](#)

Release Date: 07-24-2015 Open Date: 07-24-2015 Due Date: 10-16-2015 Close Date: 10-16-2015

The generation and dynamic interplay of redox effector molecules (e.g., oxygen, free radicals, peroxides, nitrogen oxides, and hydrogen sulfide) are fundamental features underlying the genomic, structural, metabolic and functional alterations observed in cancers.

SBIR Department of Health and Human Services

7. [NIH/NCI 351: Modulating the Microbiome to Improve Efficacy of Cancer Therapeutics](#)

Release Date: 07-24-2015 Open Date: 07-24-2015 Due Date: 10-16-2015 Close Date: 10-16-2015

Metagenomic studies in humans and animal models have established that there are alterations of the GI microbiota community during development of neoplastic and pre-neoplastic disease, and in tumor-bearing vs. healthy individuals.

SBIR Department of Health and Human Services

[8. NIH/NCI 352: Cell and Animal-Based Models to Advance Cancer Health Disparity Research](#)

Release Date: 07-24-2015 Open Date: 07-24-2015 Due Date: 10-16-2015 Close Date: 10-16-2015

Cancer health disparities (CHDs) are defined as differences in the incidence, prevalence, morbidity, and mortality that contribute to an unequal burden of cancer and represent a major public health concern both nationally and globally.

SBIR Department of Health and Human Services

[9. NIH/NCI 353: Cell-Free Nucleic Acid-Based Assay Development for Cancer Diagnosis](#)

Release Date: 07-24-2015 Open Date: 07-24-2015 Due Date: 10-16-2015 Close Date: 10-16-2015

The evidence that cell-free circulating DNA is present in cancer patient's blood was first reported over half century ago.

SBIR Department of Health and Human Services

[10. NIH/NCI 354: Companion Diagnostics for Cancer Immunotherapies](#)

Release Date: 07-24-2015 Open Date: 07-24-2015 Due Date: 10-16-2015 Close Date: 10-16-2015

The field of cancer immunotherapy has expanded rapidly over the last few years with the development of several new immunomodulatory agents that have shown promising clinical results.

SBIR Department of Health and Human Services

- [First](#)
- [Previous](#)
- [1](#)
- [2](#)
- [3](#)
- [4](#)
- [5](#)
- [6](#)
- [7](#)
- [8](#)
- [9](#)
- ...
- [Next](#)
- [Last](#)

```
jQuery(document).ready( function() { (function ($) { $('#edit-keys').attr("placeholder", 'Search Keywords'); $('span.ext').hide(); })(jQuery); });
```